Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 3 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 22Myelodysplastic Syndromes 18Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Lymphoma 12Leukemia 10Multiple Myeloma 9Hodgkin Disease 9Neuroblastoma 8Sarcoma 7Lymphoma, Non-Hodgkin 6Sarcoma, Ewing 5Primary Myelofibrosis 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Neoplasms, Plasma Cell 5Leukemia, Lymphocytic, Chronic, B-Cell 5Wilms Tumor 4Rhabdomyosarcoma 4Neuroectodermal Tumors, Primitive, Peripheral 4Medulloblastoma 4Lymphoma, Large B-Cell, Diffuse 4Leukemia, Myelomonocytic, Chronic 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Hematologic Neoplasms 4Graft vs Host Disease 4Congenital Abnormalities 4Central Nervous System Neoplasms 4Astrocytoma 4Testicular Neoplasms 3Retinoblastoma 3Optic Nerve Glioma 3

Interventions

romidepsin 8Vincristine 6Cyclophosphamide 6Specimen Handling 5Rituximab 5Biopsy 5fludarabine 4Prednisone 4Methotrexate 4Magnetic Resonance Spectroscopy 4Lactones 4Doxorubicin 4Depsipeptides 4ruxolitinib 3duvelisib 3belinostat 3Nivolumab 3Etoposide 3Dexamethasone 3Cytarabine 3Calcium Dobesilate 3Bortezomib 3Azacitidine 3tazemetostat 2sodium-iodide symporter 2pegaspargase 2merphos 2liposomal doxorubicin 2cemiplimab 2X-Rays 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Lymphoma, T-Cell × Busulfan × Clear all
NCT03259503 2025-11-10

Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant

M.D. Anderson Cancer Center

Phase 1 Completed
50 enrolled
Lymphoid

Hodgkin Disease, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡